Date: August 30- September 2nd, 2021
Organised by: Hansonwade
We’re happy to announce that our colleague Akshay Peer is attending the CAR TCR summit end of August.
With 900 advanced therapies currently under investigation and an expected 10 to 20 new therapy approvals each year from 2025 onwards, cell & gene therapy is going fast. But, it brings its own set of unique challenges to adapt. These challenges require ground- breaking work, from discovery through to commercialization.
We can already tell you that Binocs is in pole position in ex-vivo CGT / advanced therapies with an installed base in both commercial and clinical production. Currently, there are 4 commercial production CGT sites that already use Binocs today and 6 leading CGT manufacturers that are evaluating Binocs as their supply chain end-to-end planning solution.
Looking forward to meeting you!